- Home
- SURG vs MAIA Comparison
SURG vs MAIA Comparison
Compare SURG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SURG
- MAIA
- Stock Information
- Founded
- SURG 2006
- MAIA 2018
- Country
- SURG United States
- MAIA United States
- Employees
- SURG N/A
- MAIA N/A
- Industry
- SURG Advertising
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SURG Consumer Discretionary
- MAIA Health Care
- Exchange
- SURG Nasdaq
- MAIA Nasdaq
- Market Cap
- SURG 58.6M
- MAIA 56.3M
- IPO Year
- SURG N/A
- MAIA 2022
- Fundamental
- Price
- SURG $2.82
- MAIA $1.84
- Analyst Decision
- SURG Strong Buy
- MAIA
- Analyst Count
- SURG 1
- MAIA 0
- Target Price
- SURG $9.50
- MAIA N/A
- AVG Volume (30 Days)
- SURG 90.0K
- MAIA 636.1K
- Earning Date
- SURG 11-11-2025
- MAIA 11-11-2025
- Dividend Yield
- SURG N/A
- MAIA N/A
- EPS Growth
- SURG N/A
- MAIA N/A
- EPS
- SURG N/A
- MAIA N/A
- Revenue
- SURG $36,461,935.00
- MAIA N/A
- Revenue This Year
- SURG $47.01
- MAIA N/A
- Revenue Next Year
- SURG $81.15
- MAIA N/A
- P/E Ratio
- SURG N/A
- MAIA N/A
- Revenue Growth
- SURG N/A
- MAIA N/A
- 52 Week Low
- SURG $1.05
- MAIA $1.40
- 52 Week High
- SURG $3.47
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- SURG 50.29
- MAIA 64.38
- Support Level
- SURG $2.51
- MAIA $1.65
- Resistance Level
- SURG $2.90
- MAIA $1.88
- Average True Range (ATR)
- SURG 0.14
- MAIA 0.09
- MACD
- SURG -0.01
- MAIA 0.03
- Stochastic Oscillator
- SURG 56.00
- MAIA 73.33
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.